Tag: Plasmapheresis

According to the American Society for Apheresis, therapeutic plasma exchange (TPE), also known as plasmapheresis, is a medical procedure used to treat a variety of autoimmune and hematologic conditions by removing harmful substances from the blood. To prevent hypotension and maintain fluid balance, the removed plasma must be replaced with a suitable **substitute for plasma in plasmapheresis**. The choice of this replacement fluid is a critical medical decision based on the patient's specific diagnosis and clinical needs.

In the United States, a study of patients with ANCA-associated vasculitis and severe kidney issues found that about 20% received plasmapheresis [1.8.3]. A key question in this procedure is: what is the best replacement fluid for plasmapheresis?

Millions of patients worldwide depend on plasma-derived therapies for survival and improved quality of life. Answering the question, **what medicine is made from plasma?**, involves understanding how donated human plasma is processed into critical treatments for numerous rare and chronic conditions.

The most frequent adverse event reported by donors and patients undergoing apheresis is a transient tingling or numbness, a mild form of citrate toxicity which is the most common side effect of apheresis. This reaction is caused by the anticoagulant used during the procedure and is typically managed quickly and effectively by the medical staff.

First used in 1952 to manage hyperviscosity syndrome in multiple myeloma, Therapeutic Plasma Exchange (TPE) is a medical procedure that has evolved to treat numerous conditions. By filtering and replacing the liquid portion of a patient's blood, TPE works to remove harmful, disease-causing components and restore balance within the bloodstream.

As an established medical procedure, Therapeutic Plasma Exchange (TPE) is increasingly used for various autoimmune and neurological disorders where its efficacy and safety profile have shown clinical benefit. But **what is TPE treatment** and how does this process help patients by removing harmful substances from their bloodstream?

The global market for Intravenous Immunoglobulin (IVIG) was valued at $12.7 billion in 2023 and is projected to grow, yet cost, side effects, and shortages lead many to ask: **What are the alternatives to IVIG?** [1.9.4, 1.8.2] This article explores other effective immunomodulating treatments.